Health System

Latest News


Mark Wildgust, PhD, Janssen.

Mark Wildgust, PhD, vice president, Global Medical Affairs, Oncology, Janssen, speaks on progression-free survival, complete response, and overall survival benefits observed with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 and other studies presented at the 63rd Annual American Society of Hematology Meeting and Exposition.

Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center.

Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, addresses major unmet needs in Fabry disease, ranging from uncontrolled pain to irreversible damage prior to treatment initiation.